Corresponding Author: David Jiménez, MD, PhD, Respiratory Department and Medicine Department, Ramón y Cajal Hospital, IRYCIS and Alcalá University, CIBER Enfermedades Respiratorias (CIBERES), Colmenar Rd, Km. 9,100, 28034 Madrid, Spain (email@example.com).
Accepted for Publication: August 16, 2021.
Author Contributions: Dr D. Jiménez had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: D. Jimenez, Calle Rubio, Rodriguez, Bertoletti, Yusen, Monreal, Otero.
Acquisition, analysis, or interpretation of data: D. Jimenez, Agusti, Tabernero, Jara-Palomares, Hernando, Ruiz-Artacho, Perez-Peñate, Rivas-Guerrero, Rodriguez Nieto, Ballaz, Aguero, S. Jimenez, Calle Rubio, Lopez-Reyes, Marcos, Barrios, Muriel, Bertoletti, Couturaud, Huisman, Lobo, Yusen, Bikdeli, Monreal, Otero.
Drafting of the manuscript: D. Jimenez, Agusti, Marcos, Barrios, Rodriguez.
Critical revision of the manuscript for important intellectual content: D. Jimenez, Agusti, Tabernero, Jara-Palomares, Hernando, Ruiz-Artacho, Perez-Peñate, Rivas-Guerrero, Rodriguez Nieto, Ballaz, Aguero, S. Jimenez, Calle Rubio, Lopez-Reyes, Marcos, Muriel, Bertoletti, Couturaud, Huisman, Lobo, Yusen, Bikdeli, Monreal, Otero.
Statistical analysis: D. Jimenez, Marcos, Muriel, Yusen.
Obtained funding: D. Jimenez, Jara-Palomares, Barrios, Otero.
Administrative, technical, or material support: D. Jimenez, Perez-Peñate, Lopez-Reyes, Marcos.
Supervision: D. Jimenez, Agusti, Rivas-Guerrero, Calle Rubio, Marcos, Bertoletti, Huisman, Monreal, Otero.
Conflict of Interest Disclosures: Dr D. Jimenez reported receiving personal fees from Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Leo Pharma, and Pfizer and grants from Daiichi Sankyo, Rovi, and Sanofi outside the submitted work. Dr Agusti reported receiving grants and personal fees from AstraZeneca, GlaxoSmithKline, and Menarini and personal fees from Chiesi outside the submitted work. Dr Jara-Palomares reported receiving grants from Leo Pharma and MSD and personal fees from Daichii, Rovi, GlaxoSmithKline, and Actellion outside the submitted work. Dr Ruiz-Artacho reported receiving personal fees from Bristol Myers Squibb, Leo Pharma, and Daiichi Sankyo and grants from ROVI outside the submitted work. Dr Calle Rubio reported receiving personal fees from Boehringer Ingelheim, AstraZeneca, Menarini, Novartis, Grifols, and GlaxoSmithKline and consulting fees from GlaxoSmithKline, Gebro Pharma, and Novartis during the conduct of the study. Dr Bertoletti reported receiving personal fees from board, symposia, and congress travel from Actelion, Aspen, Bayer, Bristol Myers Squibb/Pfizer, Leo Pharma, and MSD and travel support from Daiichi Sankyo outside the submitted work. Dr Couturaud reported receiving grants from Bristol Myers Squibb; personal fees from Bayer, AstraZeneca, and Bristol Myers Squibb; and travel support from Bayer, Bristol-Myers Squibb, Daiichi Sankyo, Leo Pharma, InterMune, and Actelion outside the submitted work. Dr Huisman reported receiving grants from Pfizer-Bristol Myers Squibb Alliance, Bayer Health Care, ZonMw, the Dutch Heart Foundation outside the submitted work. Dr Yusen reported receiving personal fees from Ortho Pharmaceuticals for providing expert review of venous thromboembolism cases and relationship to hormonal contraceptive therapy, Organon for providing expert review of venous thromboembolism cases and relationship to hormonal contraceptive therapy, Merck for providing expert review of venous thromboembolism cases and relationship to hormonal contraceptive therapy, Portola for providing consulting related to the oral anticoagulant betrixaban, and Janssen for providing consulting related to the oral anticoagulant rivaroxaban and grants from Cyclomedica for funding as a co-investigator of a study of an imaging agent, Technegas, outside the submitted work. Dr Bikdeli reported being a consulting expert, on behalf of the plaintiff, for litigation related to 2 specific brand models of inferior vena cava filters. Dr Monreal reported receiving educational grants from Sanofi and Rovi Pharmaceuticals for research and personal fees from Sanofi and Leo Pharma for advisory committees outside the submitted work. No other disclosures were reported.
Funding/Support: This work was supported by grants from the Instituto de Salud Carlos III (PI14/00400), Chest Foundation, Sociedad Española de Neumología y Cirugía Torácica (SEPAR), Neumosur, and Daiichi Sankyo.
Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Group Information: A listing of the SLICE investigators appears in Supplement 4.
Data Sharing Statement: See Supplement 5.
Additional Contributions: We express our gratitude to S&H Medical Science Service for their quality control data, logistic, and administrative support.
M , Soler-Cataluña
JJ , Calle
et al. Spanish guidelines for management of chronic obstructive pulmonary disease (GesEPOC) 2017: pharmacological treatment of stable phase. Arch Bronconeumol
. 2017;53(6):324-335. doi:10.1016/j.arbres.2017.03.018PubMedGoogle ScholarCrossref
RA , Buist
AS , Calverley
PM , Jenkins
CR , Hurd
SS ; GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med
. 2001;163(5):1256-1276. doi:10.1164/ajrccm.163.5.2101039PubMedGoogle ScholarCrossref
J , Hurd
SS , Agustí
et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med
. 2013;187(4):347-365. doi:10.1164/rccm.201204-0596PPPubMedGoogle ScholarCrossref
JA , Garrett
JS , Sarmiento
EJ , Strachan
CC , Courtney
DM . Over-testing for suspected pulmonary embolism in American emergency departments: the continuing epidemic. Circ Cardiovasc Qual Outcomes
. 2020;13(1):e005753. doi:10.1161/CIRCOUTCOMES.119.005753PubMedGoogle Scholar
M , Söhne
M , Tick
et al; Christopher Study Investigators. The natural course of hemodynamically stable pulmonary embolism: clinical outcome and risk factors in a large prospective cohort study. Chest
. 2007;131(2):517-523. doi:10.1378/chest.05-2799PubMedGoogle ScholarCrossref
DR , Kahn
SR , Rodger
et al. Computed tomographic pulmonary angiography vs ventilation-perfusion lung scanning in patients with suspected pulmonary embolism: a randomized controlled trial. JAMA
. 2007;298(23):2743-2753. doi:10.1001/jama.298.23.2743PubMedGoogle ScholarCrossref
D , Agustí
A , Monreal
et al; SLICE investigators. The rationale, design, and methods of a randomized, controlled trial to evaluate the efficacy and safety of an active strategy for the diagnosis and treatment of acute pulmonary embolism during exacerbations of chronic obstructive pulmonary disease. Clin Cardiol
. 2019;42(3):346-351. doi:10.1002/clc.23161PubMedGoogle ScholarCrossref
S , Ahmad
D , Spyropoulos
AC , Schulman
S ; Subcommittee on Control of Anticoagulation. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost
. 2015;13(11):2119-2126. doi:10.1111/jth.13140PubMedGoogle ScholarCrossref
FE , Voets
LWLM , Simons
SO , de Mast
Q , van der Ven
AJAM , Heijdra
YF . Prevalence and localization of pulmonary embolism in unexplained acute exacerbations of COPD: a systematic review and meta-analysis. Chest
. 2017;151(3):544-554. doi:10.1016/j.chest.2016.07.034PubMedGoogle ScholarCrossref
F , López-Campos
JL , Alvarez-Martínez
et al; AUDIPOC Study Group. Clinical audit of COPD patients requiring hospital admissions in Spain: AUDIPOC study. PLoS One
. 2012;7(7):e42156. doi:10.1371/journal.pone.0042156PubMedGoogle Scholar
F , Bertoletti
L , Pastre
et al; PEP Investigators. Prevalence of pulmonary embolism among patients with COPD hospitalized with acutely worsening respiratory symptoms. JAMA
. 2021;325(1):59-68. doi:10.1001/jama.2020.23567PubMedGoogle ScholarCrossref
J , Douma
RA , Schreuder
et al. Clinical impact of findings supporting an alternative diagnosis on CT pulmonary angiography in patients with suspected pulmonary embolism. Chest
. 2013;144(6):1893-1899. doi:10.1378/chest.13-0157PubMedGoogle ScholarCrossref